Dr. Sandeep Nilkanth Athalye has been appointed as the new Global Chief Executive Officer of Kashiv BioSciences, a leading global biopharmaceutical company. With over 20 years of experience in strategic and operational roles in the global pharmaceutical sector, Dr. Athalye is set to steer the company’s growth across key markets such as the U.S., Europe, and Asia.
In his statement, Dr. Athalye emphasized Kashiv’s mission to become a top player in the biosimilars space, offering affordable and accessible solutions worldwide. He highlighted the company’s goal to stand out with a differentiated pipeline and advanced manufacturing and R&D facilities in both the U.S. and India. Dr. Athalye expressed excitement about leveraging technology and innovation to position Kashiv as a leader in biologics development.
Dr. Athalye is well-regarded for his patient-centric approach and commitment to sustainable growth. His previous leadership roles include prominent positions at Biocon Biologics, Boehringer Ingelheim, Novartis, and Schering-Plough Research Institute.
Kashiv’s Co-Founders and Board Members, Chirag and Chintu Patel, expressed enthusiasm about Dr. Athalye’s appointment, noting that his expertise will play a pivotal role as Kashiv accelerates its expansion in the growing biosimilars market.
Dr. Athalye holds an MBBS in Medicine from Bharati Vidyapeeth, a Master’s in Clinical Pharmacology from The University of Toledo, and an MBA in BioPharma Innovation from Rutgers University.
